Intersect ENT, Inc. announced that management will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at the Lotte New York Palace in New York City, and will present in a session at 9:30 a.m. ET.
MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at the Lotte New York Palace in New York City, and will present in a session at 9:30 a.m. ET.
A replay of the session will be available via the Investor Relations section of the company’s website at www.intersectENT.com. The webcast replay will be archived for approximately one month.
About Intersect ENT®
Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients. The company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.
For additional information on the company or its products, including risks and benefits, please visit www.IntersectENT.com.
XENT-F
View source version on businesswire.com: https://www.businesswire.com/news/home/20190212005038/en/
Contacts
Jeri Hilleman
650.641.2105
ir@intersectENT.com
Source: Intersect ENT, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20190212005038/en
